The targets of aspirin in bladder cancer: bioinformatics analysis

Xiao Li¹†, Yanghao Tai²†, Shuying Liu¹, Yating Gao¹, Kaining Zhang¹, Jierong Yin¹, Huijuan Zhang¹, Xia Wang¹, Xiaofei Li¹, Dongfeng Zhang¹* and Dong-feng Zhang¹*

Abstract

Background The anti-carcinogenic properties of aspirin have been observed in some solid tumors. However, the molecular mechanism of therapeutic effects of aspirin on bladder cancer is still indistinct. We introduced a bioinformatics analysis approach, to explore the targets of aspirin in bladder cancer (BC).

Methods To find out the potential targets of aspirin in BC, we analyzed direct protein targets (DPTs) of aspirin in Drug Bank 5.0. The protein-protein interaction (PPI) network and signaling pathway of aspirin DPTs were then analyzed subsequently. A detailed analysis of the KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway has shown that aspirin is linked to BC. We identified overexpressed genes in BC comparing with normal samples by Oncomine and genes that interlinked with aspirin target genes in BC by STRING.

Results Firstly, we explored 16 direct protein targets (DPT) of aspirin. We analyzed the protein-protein interaction (PPI) network and signaling pathways of aspirin DPT. We found that aspirin is closely associated with a variety of cancers, including BC. Then, we classified mutations in 3 aspirin DPTs (CCND1, MYC and TP53) in BC using the cBio Portal database. In addition, we extracted the top 50 overexpressed genes in bladder cancer by Oncomine and predicted the genes associated with the 3 aspirin DPTs (CCND1, MYC and TP53) in BC by STRING. Finally, 5 exact genes were identified as potential therapeutic targets of aspirin in bladder cancer.

Conclusion The analysis of relevant databases will improve our mechanistic understanding of the role of aspirin in bladder cancer. This will guide the direction of our next drug-disease interaction studies.

Keywords Aspirin, Bladder cancer, Target gene, Comprehensive bioinformatics analysis

Background

It is universally acknowledged that bladder cancer (BC) is one of the most common cancers, and most bladder cancers are uroepithelial, with approximately 75% of patients affected by non-muscle invasive bladder cancer (NMIBC) [1]. According to the World Health Organization (WHO), the number of BC cases and deaths is expected to increase in the future [2, 3]. Bladder cancer occurs in two different pathways originating from superficial bladder cancer (SBC), NMIBC, and muscle-invasive bladder cancer (MIBC). For many years, the treatment of BC was limited to surgery and immunotherapy or chemotherapy.
In recent years, studies on genetic analysis have guided new therapeutic approaches [4]. The FDA approved the use of the programmed death receptor ligand 1 (PD-L1) inhibitors atezolizumab and avelumab, as well as the PD-1 inhibitors nivolumab and pembrolizumab, in patients with advanced or metastatic uroepithelial cancer [5–7].

Aspirin is a powerful antiplatelet agent widely used in patients with coronary atherosclerosis [8]. guidelines published by the USPSTF affirm the benefit of aspirin in the prevention of colorectal cancer [9]. In recent years, the anticancer properties of aspirin have been observed in some solid tumors, such as prostate cancer [10], pancreatic cancer [11], and endometrial cancer [12]. However, the mechanism of action related to aspirin in bladder cancer is still unclear. In recent years, many genomic studies have identified numerous cancer-related genes, providing insight into the molecular mechanisms of disease progression. Databases combining drug data with target and drug action information have also continued to improve. The integrated analysis of cancer-associated action genes and drugs provides a good opportunity to discover new targets for drug development. A better understanding of the molecular mechanisms of pharmacological action may lead to the discovery of new applications of existing drugs.

In this study, we used bioinformatics to perform relevant analyses. First, we searched for direct protein targets (DPT) of aspirin in DrugBank. The protein interaction (PPI) network and signaling pathways of aspirin DPT were then analyzed. Analysis of the KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway showed that aspirin is associated with a variety of cancers, including bladder cancer. Next, we screened 3 genes (CCND1, MYC and TP53) as the most important target genes of aspirin in BC. Mutations in these 3 genes were analyzed using cBioPortal. Meanwhile, we compared tumors with normal groups by Oncomine to identify overexpressed genes in BC, select BC as the cancer type, and filter. Alterations in the selected cancer studies was used as a criterion of no more than 20 interactors in layers 1 and 2. We also analyzed the signaling pathways of aspirin DPTs by STRING, and then validated and visualized them by CluePedia. And the KEGG pathway of aspirin target genes in bladder cancer was identified by CluePedia. p<0.05 was set as the cut-off criterion for pathway enrichment analysis.

Exploring genomic data of aspirin DPT in BC
The cBioPortal (https://cBioportal.org) is an open platform in which we can explore multidimensional cancer genomics data. OncoPrint is a tool that allows visualization of changes in tumor samples in gene arrays [16]. With cBioPortal and OncoPrint, we explored and visualized alterations in 3 aspirin DPTs (CCND1, MYC, and TP53) associated with BC, and the frequency of genomic alterations in the selected cancer studies was used as a filter.

Identification of potential therapeutic target genes for aspirin in BC
Oncomine (https://www.oncomine.org) is a cancer microarray database and web-based data mining platform for facilitating discovery of genome-wide expression analysis. Differential gene expression is identified by comparing major types of cancer with corresponding normal tissues [17]. Oncomine was used to define overexpressed genes in BC, select BC as the cancer type, and select cancer versus normal analysis as the type of analysis for screening. Also, genes associated with 3 aspirin DPT in BC were predicted by STRING and visualized by Cytoscape. The above two data sets were crossed to

Methods
Identification of aspirin direct protein targets (DPT)
DrugBank (https://go.drugbank.com/) is an annotated rich resource that combines detailed drug data with comprehensive drug target and action information. Since its initial release in 2006, DrugBank has been used extensively to facilitate electronic drug target discovery, drug design, drug docking or screening, drug metabolism prediction, drug interaction prediction, and general pharmacy education. A wealth of drug metabolomics, drug proteomics, and drug transcriptomics information has been compiled from the primary literature [13]. The direct protein target (DPT) of aspirin was obtained from Drugbank.

2.2 Protein-protein interaction (PPI) networks and signaling pathways analyzed by aspirin DPTs
STRING (https://string-db.org/) is an online tool designed to evaluate protein-protein interaction (PPI) networks. Cytoscape is an open-source software project for integrating biomolecular interaction networks with high-throughput expression data and other molecular states into a unified conceptual framework [14]. CluePedia, a plug-in for Cytoscape software, is a tool to search for potential genes associated with specific signaling pathways by calculating linear and nonlinear statistical correlations of experimental data [15]. The PPI network of aspirin DPTs consists of STRING with a cutoff criterion of no more than 20 interactors in layers 1 and 2. We also analyzed the signaling pathways of aspirin DPTs by STRING, and then validated and visualized them by CluePedia. And the KEGG pathway of aspirin target genes in bladder cancer was identified by CluePedia. p<0.05 was set as the cut-off criterion for pathway enrichment analysis.
Table 1 Identification of direct targets of aspirin using DRUGBANK.

| DB_ID   | Name                | Gene name | Uniprot ID | Action       |
|---------|---------------------|-----------|------------|--------------|
| DB00945 | Acetylsalicylec acid| PTGS1     | P23219     | Inhibitor    |
|         | PTGS2               | P23219    | P25354     | Inhibitor    |
|         | AKR1C1              | Q99519    | Q04828     | Inhibitor    |
|         | PRKAA1              | Q13131    | Q13131     | Activator    |
|         | EDNRA               | P25101    | P25101     | Inhibitor    |
|         | TP53                | P04636    | P04636     | Inducer      |
|         | HSP52               | P11021    | P11021     | Inhibitor Binder |
|         | RPS6KA3             | P51812    | P51812     | Inhibitor    |
|         | NFKBIA              | P25963    | P25963     | Inhibitor    |
|         | TNFAIP6             | P98066    | P98066     | Inhibitor    |
|         | CASP1               | P29466    | P29466     | Inhibitor    |
|         | CASP3               | P42574    | P42574     | Inhibitor    |
|         | CCND1               | P24385    | P24385     | Downregulator |
|         | MYC                 | P01106    | P01106     | Inhibitor    |
|         | PCNA                | P12004    | P12004     | Inhibitor    |
|         | NEU1                | Q09919    | Q09919     | Inhibitor    |

obtain potential therapeutic target genes for aspirin in BC. A cut-off value of p<0.05 was used.

Gene Ontology analysis of potential therapeutic target genes for aspirin in bladder cancer
Gene Ontology (GO; http://www.geneontology.org/) is a community-based bioinformatics resource that uses ontologies to represent biological knowledge and provide information about the function of gene products [18]. GO analysis was used to determine the functional annotation of potential therapeutic target genes for aspirin in BC. First, Homo sapiens was used as a biological filter. Next, biological processes, molecular functions, or cellular components were set as GO-level filters. Then, select the data provided by GO_Central. Finally, we confirmed the first GO term as the most important function of potential therapeutic target genes of aspirin in BC.

Results
Identification of aspirin DPT
In the DrugBank output, aspirin is described as an analgesic, non-narcotic anti-inflammatory agent, non-steroidal anti-inflammatory agent, antipyretic agent, antirheumatic agent, cardiovascular agent, central nervous system agent, cyclooxygenase inhibitor, platelet aggregation inhibitor, and sensory system agent. We identified a total of 16 major direct protein targets (DPT) of aspirin including PTGS1, PTGS2, AKR1C1, PRKAA1, EDNRA, TP53, HSPA5, RPS6KA3, NFKBIA, TNFAIP6, CASP1, CASP3, CCND1, MYC, PCNA, NEU1 (Table 1).

Table 2 Top 5 KEGG pathways associated with the DPTs of aspirin

| pathway | description       | count | false discovery rate | Gene ID       |
|---------|-------------------|-------|----------------------|---------------|
| hsa05216| Thyroid cancer    | 3     | 0.00011              | TP53, CCND1, MYC |
| hsa05219| Bladder cancer    | 3     | 0.00014              | TP53, CCND1, MYC |
| hsa05222| Small cell lung cancer | 6 | 3.48E-08 | PTGS2, NFKBIA, CASP3, TP53, CCND1, MYC |
| hsa05134| Legionellosis     | 3     | 0.00029              | NFKBIA, CASP1, CASP3 |
| hsa05220| Chronic myeloid leukemia | 4 | 1.68E-05 | TP53, CCND1, MYC, NFKBIA |

Direct association of aspirin with bladder cancer
The PPI network and signaling pathways of 16 aspirin DPTs were generated by STRING (Table 2); the top 5 KEGG pathways of DPTs were thyroid cancer, bladder cancer, small cell lung cancer, legionellosis, and chronic granulocytic leukemia. The results showed that aspirin was associated with bladder cancer (p<0.00014) and three aspirin DPTs (CCND1, MYC, and TP53) were associated with BC (Table 2). We then validated and visualized the association of aspirin with BC by CluePedia (Fig. 1B). The three DPTs associated with BC by aspirin were consistent with the results of STRING (Fig. 1).

Genetic alterations of aspirin DPTs in patients with bladder cancer
To understand the expression and function of the three aspirin DPTs associated with BC (CCND1, MYC, and TP53), the genetic alterations of these genes in BC patients were explored through the cBioportal. We examined cancer genomic alterations and clinical expression characteristics of CCND1, MYC and TP53 in bladder cancer. We obtained a summary of the polygenic alterations by studying MSKCC, TCGA, and MSK/TCGA. The most significant genomic alterations were presented using OncoPrint. The results showed that 646 cases (70%) had at least one alteration in CCND1, MYC, and TP53 (Fig. 2). alterations in CCND1 were presented as gene amplification. alterations in MYC were mainly presented as gene amplification. alterations in TP53 mainly included missense mutations, splice mutations and truncation mutations (Fig. 2).

Prediction of BC-associated genes with 3 aspirin DTPs
Based on the information in the STRING database, the PPI network of genes and the 3 aspirin DPTs in BC were obtained (Fig. 3), and we identified many aspirin-related genes. KEGG pathway analysis showed that these genes are mainly involved in Cell cycle, Human T-cell leukemia...
Identification of overexpressed genes in bladder cancer
We identified overexpressed genes in BC by comparing BC samples with normal tissues in the Oncomine online database. The top 50 genes overexpressed in 129 BC samples were identified (Fig. 4). The analysis showed that the top 50 genes were mainly enriched in Cell cycle, Oocyte meiosis, Progesterone-mediated oocyte maturation, p53 signaling pathway, Cellular senescence, Human T-cell leukemia virus 1 infection (Table 3).

Identification of potential therapeutic target genes of aspirin in bladder cancer
By comparing the overexpressed genes in BC and the three genes associated with aspirin DPT in BC, we identified five genes GSK3B, CDC20, TPX2, AURKA and CCNE1 (Fig. 5; Table 5) as potential therapeutic targets of aspirin in BC.
Analysis of potential target genes for aspirin treatment of bladder cancer

Analysis of the KEGG pathway for these five genes showed that GSK3B, CDC20 and CCNE1 are involved in the cell cycle and AURKA is involved in oocyte meiosis (Fig. 6). Functional annotation of these five genes showed that CDC20 was mainly involved in anaphase-promoting complex-dependent catabolic process, TPX2 was mainly involved in microtubule binding, AURKA was mainly involved in regulation of cytokinesis, CCNE1 was mainly involved in regulation of cyclin-dependent protein serine/threonine kinase activity, and GSK3B was negatively associated with the classical Wnt signaling pathway regulation was associated (Table 6).

Discussion

BC is one of the most common cancers and patients with early or limited BC can be treated by surgical resection, while patients with advanced BC are usually treated with radiotherapy or chemotherapy. Despite effective treatment, the outcome is still unsatisfactory [19]. Bladder cancer is considered to be one of the most frequently mutated cancers in humans, with a mutation rate second only to lung and skin cancers [20, 21]. The major mutation among these mutations is the promoter mutation in the gene encoding telomerase reverse transcriptase (TERT), which occurs at a frequency of 70–80% in bladder cancer patients [22–25]. Therefore, it is essential to find potential therapeutic targets for bladder cancer.
as soon as possible. And a large number of studies have shown that regular aspirin consumption can reduce the risk of cancer [26–28].

In the present study, we used comprehensive bioinformatics analysis to elucidate the molecular roles of aspirin and its target proteins in BC. First, we analyzed aspirin by [1] identifying the primary DPT of aspirin using Drug Bank [2]. Protein–protein interaction (PPI) networks and signaling pathways of aspirin DPT were analyzed using STRING [3]. Detection and testing of genetic alterations using the cBio portal. [4] Identification of genes associated with 4 aspirin target genes in BC using STRING. We identified 16 action targets of aspirin: PTGS1, PTGS2, AKR1C1, PRKAA1, EDNRA, TP53, HSPA5, RPS6KA3, NFKBIA, TNFAIP6, CASP1, CASP3, CCND1, MYC, PCNA, CCNA2. Among them, CCND1, MYC, and TP53 were associated with BC. Subsequently, we determined that the alteration of CCND1 showed gene amplification. The alteration of MYC mainly showed gene amplification. The alteration of TP53 mainly included missense mutation, splice mutation and truncation mutation. Finally, we constructed a PPI pathway consisting of three target genes of BC to predict the potential target genes of aspirin in BC. Meanwhile, we identified the top 50 overexpressed genes of BC using Oncomine. Finally, we identified the co-expressed genes (GSK3B, CDC20, TPX2, AURKA and CCNE1) among the genes interlinked with the 3 aspirin target genes in BC samples as potential targets for aspirin treatment of BC.

GSK-3β, GSK3B, is a positive regulator of NF-κB transcriptional activity [29, 30]. It has been shown that NF-κB plays a role in human cancer progression and chemoresistance [31, 32] through positive regulation of its target genes XIAP [33] and Bcl-2 [34]. Levidou et al. [32] showed that nuclear expression of NF-κB correlates with histological grading and staging of bladder cancer. Sei Naito et al. found that urothelial epithelial carcinoma cells and abnormal nuclear accumulation of GSK-3β in most human bladder cancers. Nuclear expression of GSK-3β was associated with high malignancy, metastasis and poorer survival in bladder cancer patients. They suggested that GSK-3 is a positive regulator of bladder cancer cell proliferation and survival [35]. cdc20 is usually considered as an oncogenic factor that promotes tumor development [36, 37]. Moreover, it has been demonstrated that increased CDC20 expression in bladder cancer patients is associated with poor prognosis [38]. AURKA and AURKB, of the AURKA kinase family, are closely associated with the development of malignancy. AURKA is a cell cycle-associated serine-threonine kinase that is overexpressed in various types of cancer and is strongly associated with poor prognosis [39]. Mobley et al. [40] found that knockdown AURKA had little effect on bladder cancer cell proliferation but prevented tumor cell invasion, and that overexpression of AURKA was associated with poor prognosis. AURKB is a key regulator of malignant mitosis and is involved in chromosome segregation and cytoplasmic division. Bufo et al. [41] found that high expression of AURKB may be involved in bladder carcinogenesis and hypothesized that bladder cancer could be treated in the future by targeting AURKB.

Table 3 TOP 5 KEGG pathways in the PPI of the DPTs of aspirin.

| Pathway                                      | Count | Strength | False Discovery Rate | Gene ID                                                                 |
|----------------------------------------------|-------|----------|----------------------|-------------------------------------------------------------------------|
| **Cell cycle**                               | 23    | 1.77     | 3.61E-31             | CCND1, CDKN1B, CDK4, MDM2, CCND2, CREBBP, CCNE1, CDK2, RB1, TP53,      |
|                                              |       |          |                      | SKP2, CDK2, TP53, CCNA2, SKP2, CDK2, TP53, CCNA2, SKP2, CDK2, TP53,    |
|                                              |       |          |                      | SKP2, CDK2, TP53, CCNA2, SKP2, CDK2, TP53, CCNA2, SKP2, CDK2, TP53,    |
|                                              |       |          |                      | SKP2, CDK2, TP53, CCNA2, SKP2, CDK2, TP53, CCNA2, SKP2, CDK2, TP53,    |
|                                              |       |          |                      | SKP2, CDK2, TP53, CCNA2, SKP2, CDK2, TP53, CCNA2, SKP2, CDK2, TP53,    |
| Human T-cell leukemia virus 1 infection      | 21    | 1.49     | 5.40E-23             | KAT2A, CCND1, CDK4, CCND2, CREBBP, CCNE1, CDKN2C, EP300, CDK6,       |
|                                              |       |          |                      | CDK2, RB1, TP53, CCNA2, SKP2, CDK2, TP53, CCNA2, SKP2, CDK2, TP53,    |
|                                              |       |          |                      | SKP2, CDK2, TP53, CCNA2, SKP2, CDK2, TP53, CCNA2, SKP2, CDK2, TP53,    |
|                                              |       |          |                      | SKP2, CDK2, TP53, CCNA2, SKP2, CDK2, TP53, CCNA2, SKP2, CDK2, TP53,    |
| Viral carcinogenesis                         | 20    | 1.53     | 9.44E-23             | KAT2A, CCND1, CDK4, MDM2, CCND2, CREBBP, CCNE1, CDKN2C, EP300, CDK6, |
|                                              |       |          |                      | CDK2, RB1, TP53, CCNA2, SKP2, CDK2, TP53, CCNA2, SKP2, CDK2, TP53,    |
|                                              |       |          |                      | SKP2, CDK2, TP53, CCNA2, SKP2, CDK2, TP53, CCNA2, SKP2, CDK2, TP53,    |
|                                              |       |          |                      | SKP2, CDK2, TP53, CCNA2, SKP2, CDK2, TP53, CCNA2, SKP2, CDK2, TP53,    |
| p53 signaling pathway                       | 16    | 1.84     | 2.22E-22             | CCND1, CDK4, MDM2, CCND2, CCNE1, CDK6, CDK2, TP53, ATM, BCL2L1, RCHY1,|
|                                              |       |          |                      | SFN, CCNG1, MDM4, PTEN, CCND3                                                |
| Pathways in cancer                          | 23    | 1.14     | 2.48E-18             | CCND1, CDKN1B, CDK4, MDM2, CCND2, CREBBP, CCNE1, EP300, CDK6, CDK2,   |
|                                              |       |          |                      | RB1, TP53, CCNA2, SKP2, CDK2, TP53, CCNA2, SKP2, CDK2, TP53, CCNA2,    |
|                                              |       |          |                      | SKP2, CDK2, TP53, CCNA2, SKP2, CDK2, TP53, CCNA2, SKP2, CDK2, TP53,    |
|                                              |       |          |                      | SKP2, CDK2, TP53, CCNA2, SKP2, CDK2, TP53, CCNA2, SKP2, CDK2, TP53,    |
|                                              |       |          |                      | SKP2, CDK2, TP53, CCNA2, SKP2, CDK2, TP53, CCNA2, SKP2, CDK2, TP53,    |
|                                              |       |          |                      | SKP2, CDK2, TP53, CCNA2, SKP2, CDK2, TP53, CCNA2, SKP2, CDK2, TP53,    |

as soon as possible. And a large number of studies have shown that regular aspirin consumption can reduce the risk of cancer [26–28].

In the present study, we used comprehensive bioinformatics analysis to elucidate the molecular roles of aspirin and its target proteins in BC. First, we analyzed aspirin by [1] identifying the primary DPT of aspirin using Drug Bank [2]. Protein–protein interaction (PPI) networks and signaling pathways of aspirin DPT were analyzed using STRING [3]. Detection and testing of genetic alterations using the cBio portal. [4] Identification of genes associated with 4 aspirin target genes in BC using STRING. We identified 16 action targets of aspirin: PTGS1, PTGS2, AKR1C1, PRKAA1, EDNRA, TP53, HSPA5, RPS6KA3, NFKBIA, TNFAIP6, CASP1, CASP3, CCND1, MYC, PCNA, CCNA2. Among them, CCND1, MYC, and TP53 were associated with BC. Subsequently, we determined that the alteration of CCND1 showed gene amplification. The alteration of MYC mainly showed gene amplification. The alteration of TP53 mainly included missense mutation, splice mutation and truncation mutation. Finally, we constructed a PPI pathway consisting of three target genes of BC to predict the potential target genes of aspirin in BC. Meanwhile, we identified the top 50 overexpressed genes of BC using Oncomine. Finally, we identified the co-expressed genes (GSK3B, CDC20, TPX2, AURKA and CCNE1) among the genes interlinked with the 3 aspirin target genes in BC samples as potential targets for aspirin treatment of BC.

GSK-3β, GSK3B, is a positive regulator of NF-κB transcriptional activity [29, 30]. It has been shown that NF-κB plays a role in human cancer progression and chemoresistance [31, 32] through positive regulation of its target genes XIAP [33] and Bcl-2 [34]. Levidou et al. [32] showed that nuclear expression of NF-κB correlates with histological grading and staging of bladder cancer. Sei Naito et al. found that urothelial epithelial carcinoma cells and abnormal nuclear accumulation of GSK-3β in most human bladder cancers. Nuclear expression of GSK-3β was associated with high malignancy, metastasis and poorer survival in bladder cancer patients. They suggested that GSK-3 is a positive regulator of bladder cancer cell proliferation and survival [35]. cdc20 is usually considered as an oncogenic factor that promotes tumor development [36, 37]. Moreover, it has been demonstrated that increased CDC20 expression in bladder cancer patients is associated with poor prognosis [38]. AURKA and AURKB, of the AURKA kinase family, are closely associated with the development of malignancy. AURKA is a cell cycle-associated serine-threonine kinase that is overexpressed in various types of cancer and is strongly associated with poor prognosis [39]. Mobley et al. [40] found that knockdown AURKA had little effect on bladder cancer cell proliferation but prevented tumor cell invasion, and that overexpression of AURKA was associated with poor prognosis. AURKB is a key regulator of malignant mitosis and is involved in chromosome segregation and cytoplasmic division. Bufo et al. [41] found that high expression of AURKB may be involved in bladder carcinogenesis and hypothesized that bladder cancer could be treated in the future by targeting AURKB.
expression and specific antimitotic agents. dysregulation of CCNE1/2 activity is present in various cancers

Fig. 4 The top 50 over-expressed genes in bladder cancer vs. normal tissue using the Oncomine database
leading to disruption of the G1-S transition and uncontrolled cell proliferation. Involvement of the CCNE-CDK2 complex in cell cycle regulation has been demonstrated to play an important role in tumor development. The E2F transcription factor strongly activates CCNE1 and CCNE2, the CCNE-CDK2 complex phosphatases and inactivates Rb, and phosphorylated Rb releases the E2F transcription factor, thus promoting cell cycle progression from G1 to S phase. In addition, it has been demonstrated that MNX1 induces bladder cancer proliferation and tumorigenicity by targeting promoters to upregulate CCNE1 and CCNE2 expression.

As for the TPX2 gene, by String prediction, we learned that no complete biological process, signaling pathway related to TPX2 has been found so far. However, there are many literatures that have demonstrated that TPX2 is significantly associated with bladder cancer. Liang Yan et al. demonstrated that overexpression of TPX2 promotes bladder cancer growth, while overexpression of GLIPR1 or p53 inhibits bladder cancer growth. Increasing evidence supports the role of TPX2 as a tumor promoter in human tumor development, with bladder cancer tissues expressing high TPX2 levels having upregulated p53 expression and downregulated GLIPR1 expression. In addition, TPX2 and p53 expression was lower in non-muscle-infiltrating bladder cancer cells than in muscle-infiltrating bladder cancer cells, while the opposite pattern of GLIPR1 expression was observed. Overexpression of GLIPR1 suppressed TPX2, meanwhile, SP1 and c-Myb expression were negatively correlated with expression of GLIPR1 suppressed TPX2. Meanwhile, SP1 and c-Myb expression were negatively correlated with expression of GLIPR1 suppression in patients with bladder cancer. In addition, TPX2 promotes T24 cell proliferation and tumorigenesis and blocks apoptosis.

In conclusion, we believe that these five target genes (GSK3β, CDC20, TPX2, AURKA and CCNE1) may promote the occurrence of bladder cancer and lead to poor prognosis. We explored the potential therapeutic targets of aspirin for bladder cancer by comprehensive bioinformatics analysis. We suggest that aspirin acts through cell cycle and signaling pathways in bladder cancer cells, and our results aim to provide new clues to elucidate the mechanisms of aspirin’s action in bladder cancer.

However, there are still challenges in applying Web-based data to the study of drugs such as aspirin.

Table 4 KEGG pathways in the top 50 over-expressed genes in bladder cancer vs. normal tissue

| term description | count | false discovery rate | Gene ID |
|------------------|-------|----------------------|---------|
| Cell cycle       | 12    | 1.76E-13             | CCNB1, ESPL1, MCM4, CCNE1, MCM2, BUB1B, CCNB2, CDC25A, GSK3β, CDC20, PTTG1, CDK1 |
| Oocyte meiosis   | 9     | 6.48E-09             | MAPK13, AURKA, CCNB1, ESPL1, CCNE1, CCNB2, CDC20, PTTG1, CDK1 |
| Progesterone- mediated oocyte maturation | 6 | 2.67E-05 | MAPK13, AURKA, CCNB1, CCNB2, CDC25A, CDK1 |
| p53 signaling pathway | 5 | 0.00015 | CCNB1, CCNE1, CCNB2, RRM2, CDK1 |
| Cellular senescence | 6 | 0.00022 | MAPK13, CCNB1, CCNE1, CCNB2, CDC25A, CDK1 |
| Human T-cell leukaemia virus 1 infection | 6 | 0.0012 | ESPL1, CCNE1, BUB1B, CCNB2, CDC20, PTTG1 |

Table 5 Identification of co-expressed genes from two gene groups

| Names | total elements |
|-------|----------------|
| DPT(A) | 58 |
| DPT(B) | 44 |
| Cancer(B) | 4 |

Fig. 5 Venn diagram between the overexpressed genes and the three genes associated with aspirin

[42–45]
Identifying drug-target interactions is important in the drug discovery process. Although microarrays, proteomics and other high-throughput screening analyses have been applied, experimental methods for drug-target interaction identification remain challenging.

**Conclusion**
In short, comprehensive bioinformatics analysis provides researchers with a simple and convenient method that can use existing drug information and cancer genetic changes as a guide for testing hypotheses and help researchers apply basic research to the clinic.
Table 6  Genetic analysis of potential therapeutic target genes of aspirin in bladder cancer

| Gene symbol | Gene name                                      | GO term                                    | Gene function                                      |
|-------------|-----------------------------------------------|--------------------------------------------|----------------------------------------------------|
| GSK3B       | Glycogen synthase kinase-3 beta               | GO:0000090                                 | negative regulation of canonical Wnt signaling pathway |
| CDC20       | Cell division cycle protein 20 homolog       | GO:0008054                                 | anaphase-promoting complex-dependent catalytic process |
| TPX2        | Targeting protein for XKLP2                  | GO:0008017                                 | microtubule binding                                |
| AURKA       | Aurora kinase A                              | GO:0032465                                 | regulation of cytokinesis                           |
| CCNE1       | G1/S-specific cyclin-E1                      | GO:0000079                                 | regulation of cyclin-dependent protein serine/threonine kinase activity |

List of abbreviations

[BC] bladder cancer
[NMIBC] Non-muscle invasive bladder cancer
[PD-L1] Programmed death receptor ligand 1
[KEGG] Kyoto Encyclopedia of Genes and Genomes.
[DPTs] Protein targets.
[PPi] Protein-protein interaction.

Acknowledgements

Not applicable.

Authors’ contributions

(I) Conception and design: D.Z.; (II) Administrative support: H.Z., X.W., X.L.; (IV) Collection and assembly of data: Y.G.S., L.; (V) Data analysis and interpretation: X.L., Y.T.; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Funding

Not applicable.

Data availability

All data generated or analyzed during this study are included in this published article.

Declarations

Ethics approval and consent to participate

Since the study is based on public data, the informed consent and ethical approval are not required.

Consent for publication

Not applicable.

Competing interests

The authors have no relevant financial or non-financial interests to disclose.

Received: 31 March 2022 / Accepted: 10 October 2022

Published online: 31 October 2022

References

1. Weyers Y, Arends TJH, et al. Management of low-risk and intermediate-risk non-muscle-invasive bladder carcinoma. Hematol Oncol Clin North Am. 2015 Apr;29(2):219–25.
2. Patchan A, Sodahl G, Chebil G, et al. A molecular pathologic framework for risk stratification of stage T1 urothelial carcinoma. Eur Urol. 2015 Nov;68(S):824–832; discussion 835–836.
3. Robertson AG, Kim J, Al-Ahmadeh H, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2018 Aug 9;174(4):1033.
4. Gandhi NM, Baras A, Munari E, et al. Gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: predicting response and assessing outcomes. Urol Oncol. 2015 May;33(5):204.e1-e7.
5. Kujtan L, Hussain A, Subramanian J, et al. The evolving genomic landscape in urothelial cancer. Curr Opin Oncol. 2018 May;30(3):197–202.
6. Weinstein JN, Akbani R, Broom BM, et al. Comprehensive molecular characterization of urothelial bladder cancer. Nature. 2014 Mar 20;507(7492):315–322.
7. Sjødahl G, Laus M, Lovgren K, et al. A molecular taxonomy for urothelial carcinoma. Clin Cancer Res. 2012 Jun 15;18(12):3377–3386.
8. Antoniadis C, Tousoulis D, Stefanadis C. Nitric oxide-releasing aspirin: will it stay NO to atherothrombosis? Int J Cardiol. 2007 May;112(2):170–2. 118.
9. Biberenz-Domingo K. Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer. U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2016 Jun 21;164(12):836–45. 164.
10. Assayag J, Pollak MN, Azoulay L. The use of aspirin and the risk of mortality in patients with prostate cancer. J Urol. 2015;193(4):1220–5.
11. Friedrich V, Chen N-M, Neef M, et al. The angiotensin-converting enzyme inhibitor enalapril and aspirin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer. Gut. 2010 May;59(5):630–7.
12. Matsuo K, Sigita S, Cahon K, Yoshihara, et al. Association of Low-Dose Aspirin and Survival of Women with Endometrial Cancer. Obstet Gynecol. 2016 Jul;128(1):237–37.
13. David S, Wishart YD, Feunang, An C, Guo, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1): D1074-D1082.
14. Damian Szkarczyk AK, Gable KC, Nastou, et al. The STRING database in 2021: customizability of protein–protein networks, and functional characterization of user-uploaded gene/measurement sets. Nucleic Acids Res. 2021 Jan;49(D1):D605–12. 49.
15. Gabriela Bindea J, Galon B, Milenic. CluePedia Cytoscape plugin: pathway insights using integrated experimental and in silico data. Bioinformatics. 2013 Mar 1;29(5):661–663.
16. Ethan Cerami J, Gao U, Dogrusoz, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012 May;2(5):401–4.
17. Daniel R, Rhodes J, Yu K, Shanker, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia. Jan-Feb. 2004;6(1):1–6.
18. Gene Ontology Consortium. Gene Ontology Consortium: going forward. Nucleic Acids Res. 2015 Jan;43(Database issue):D1049–56.
19. Guillaume L, Guy L. Epidemiology of and risk factors for bladder cancer and for urothelial tumors. Rev Prat. 2014 Dec;64(10):1372–4, 1378–1380.
20. Lawrence MS, Stojanov P, Paz Polak, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013 Jul;11(7475):214–8. 499.
21. Ludmil B, Alexandrov S, Nik-Zainal DC, Wedge, et al. Signatures of mutational processes in human cancer. Nature. 2013 Aug 22;507(7492):315–322.
22. Rachakonda PS, Hosen I, Petra J, de Verdier, et al. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. Proc Natl Acad Sci U S A. 2013 Oct 22;110(43):17426–17431.
23. Ricardo Leão D, Lee A, Figueiredo, et al. Combined genetic and epigenetic alterations of the TERT promoter affect clinical and biological behavior of bladder cancer. Int J Cancer. 2019 Apr;144(7):1912–20.
24. Boaz Kurtis J, Zhuge C, Ojima, et al. Recurrent TERT promoter mutations in urothelial carcinoma and potential clinical applications. Ann Diagn Pathol. 2016 Apr;21:7–11.
25. Yves Allory W, Beukers A, Sagera, et al. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. Eur Urol. 2014 Feb;65(2):360–6.
26. Nancy R, Cook I-Min, Lee, Shumin M, Zhang, et al. Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med. 2013 Jul;162(7):77–85. 159.
27. Patrignani P, Patrono C. Aspirin and Cancer. J Am Coll Cardiol. 2016 Aug;68(9):967–76. 68.
28. Thorat MA. and J. Cuzick. Role of aspirin in cancer prevention. Curr Oncol Rep. 2013 Dec;15(6):533–40.
29. Ougolov AV, Bone ND. Fernandez-Zapico ME, et al Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor κB.
target genes and induction of apoptosis in chronic lymphocytic leukemia B cells. Blood. 2007 Jul 15;110(2):735–742.

30. Ougolkov AV, Fernandez-Zapico ME, Bilim VN, et al. Aberrant nuclear accumulation of glycogen synthase kinase-3β in human pancreatic cancer: association with kinase activity and tumor dedifferentiation. Clin Cancer Res. 2006 Sep 1;12(17):5074–5081.

31. Tas SW, Vervoordeldonk MJ, Tak PP. Gene therapy targeting nuclear factor-xB: towards clinical application in inflammatory diseases and cancer. Curr Gene Ther. 2009 Jun;9(3):160–70.

32. Levidou G, Saetta AA, Korkolopoulou P, et al. Clinical significance of nuclear factor (NF)-κB levels in urothelial carcinoma of the urinary bladder. Virchows Arch. 2008 Mar;452(3):295–304.

33. Stehlik C, de Martin R, Kumabashiri I, et al. Nuclear factor (NF)-κB-regulated X-chromosome-linked iap gene expression protects endothelial cells from tumor necrosis factor α-induced apoptosis. J Exp Med. 1998 Jul 6;188(1):211–216.

34. Zong WX, Edelstein LC, Chen C, et al. The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcripational target of NF-κB that blocks TNFα-induced apoptosis. Genes Dev. 1998 Mar 1;13(3):256–267.

35. Sei Naito V, Bilim K, Yuuki, et al. Glycogen Synthase Kinase-3β: A Prognostic Marker and a Potential Therapeutic Target in Human Bladder Cancer. Clin Cancer Res. 2010 Nov 1;16(21):5124–5132.

36. Kidokoro T, Tanikawa C, Furukawa Y, et al. CDC20, a potential cancer therapeutic target, is negatively regulated by p53. Oncogene. 2008 Mar 6;27(11):1562–1571.

37. Wang Z, Wan L, Zhong J, et al. CDC20: a potential novel therapeutic target for cancer treatment. Curr Pharm Des. 2013;19(18):3210–4.

38. Choi J, Kim Y, Lee J, et al. High expression of spindle assembly checkpoint proteins CDC20 and MAD2 is associated with poor prognosis in urothelial bladder cancer. Virchows Arch. 2013 Nov;463(5):681–7.

39. Marampon F, Gravina GL, Popov VM, et al. Close correlation between MEK/ERK and Aurora-B signaling pathways in sustaining tumorigenic potential and radiosensitivity of gynecological cancer cell lines. Int J Oncol. 2014 Jan;44(1):285–94.

40. Mobley A, Zhang S, Bondaruk J, et al. Aurora kinase a is a biomarker for bladder cancer detection and contributes to its aggressive behavior. Sci Rep. 2017 Jan;17;40714.

41. Bufo P, Sanguedolce F, Tortorella S, et al. Expression of mitotic kinases phospho-aurora A and aurora B correlates with clinical and pathological parameters in bladder neoplasms. Histol Histopathol. 2010 Nov;25(11):1371–7.

42. Natarajan R, Mackay A, Wilkerson PM, et al. Functional characterization of the 19q12 amplicon in grade III breast cancers. Breast Cancer Res. 2012 Mar 20;14(2):R35.

43. Au-Yeung G, Lang F, Azar WJ, et al. Selective targeting of cyclin E1-amplified high-grade serous ovarian Cancer by cyclin-dependent kinase 2 and AKT inhibition. Clin Cancer Res. 2017 Apr;13(7):1862–1874.

44. Erdmann K, Kaulke K, Rieger C, et al. MiR-26a and miR-138 block the G1/S transition by targeting the cell cycle regulatory network in prostate cancer cells. J Cancer Res Clin Oncol. 2016 Nov;142(11):2249–61.

45. da Silva GN, de Camargo EA, Salvadori DM. Toxicogenic activity of gemcitabine in two TP53-mutated bladder cancer cell lines: special focus on cell cycle-regulated genes. Mol Biol Rep. 2012 Dec;39(12):10373–82.

46. Tashiro E, Tsuchiya A, Imoto M. Functions of cyclin D1 as an oncogene and regulation of cyclin D1 expression. Cancer Sci. 2007 May;98(5):629–35.

47. Deane NG, Parker MA, Aramandla R, et al. Hepatocellular carcinoma results from chronic cyclin D1 overexpression in transgenic mice. Cancer Res. 2001 Jul;61(14):5389–5395.

48. Aghgar U, Witkiewicz AK, Turner NC, et al. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov. 2015 Feb;14(2):130–46.

49. Chen M, Wu R, Li G, et al. Motor neuron and pancreas homeobox 1 (HHLB9) promotes sustained proliferation in bladder cancer by upregulating CCNE1/2. J Exp Clin Cancer Res. 2018 Jul;37(1):154.

50. Liao Y, Li Q, Yang J, et al. TPX2-p53-GIT1 regulatory circuitry in cell proliferation, invasion and tumor growth of bladder cancer. J Cell Biochem. 2018 Feb;119(2):1791–803.

51. Huang Y, Guo W, Kan H. TPX2 is a prognostic marker and contributes to growth and metastasis of hepatocellular carcinoma. Int J Mol Sci. 2014 Oct;9;5(10):18146–18161.

Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.